Merck & Co., Inc. is 161.6x more valuable than Avidity Biosciences, Inc. by market capitalization ($293.16 B vs $1.81 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RNA | MRK |
|---|---|---|
| Market cap | $1.81 B | $293.16 B |
| US-listed rank | #2174 | #44 |
| Revenue (latest FY) | $18.75M | $65.01B |
| Net income (latest FY) | -$684.63M | $18.25B |
| Net margin | -3650.4% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 547 | 996 |
Merck & Co., Inc. is 161.6x more valuable than Avidity Biosciences, Inc. by market capitalization ($293.16 B vs $1.81 B).
In their latest fiscal years, Avidity Biosciences, Inc. reported $18.75M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Avidity Biosciences, Inc. and Merck & Co., Inc., or browse the full rankings.